NEW YORK, May 15 – Beyond Genomics said Tuesday it has entered its first corporate partnership, penning a deal with Elan Pharmaceuticalsto apply its systems biology techniques for Alzheimer's research.

In exchange for Beyond Genomics’ two-year commitment to the program, during which the companies will seek to find biomarkers and drug targets for Alzheimer's disease, Elan made a $5 million equity investment in the company.

Beyond Genomics did not disclose any more financial details.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.